| Too few, too weak: conflict of interest policies at Canadian medical schools A Shnier, J Lexchin, B Mintzes, A Jutel, K Holloway PloS one 8 (7), e68633, 2013 | 45 | 2013 |
| Normalizing complaint: Scientists and the challenge of commercialization KJ Holloway Science, Technology, & Human Values 40 (5), 744-765, 2015 | 32 | 2015 |
| ‘Something there is that doesn’t love a wall’: Histories of the placental barrier A Martin, K Holloway Studies in History and Philosophy of Science Part C: Studies in History and …, 2014 | 15 | 2014 |
| Uneasy subjects: Medical students' conflicts over the pharmaceutical industry K Holloway Social Science & Medicine 114, 113-120, 2014 | 12 | 2014 |
| Health Canada needs to act on laboratory-developed diagnostics K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth | 6 | 2019 |
| A responsibility to commercialize? Tracing academic researchers’ evolving engagement with the commercialization of biomedical research KHM Herder Journal of Responsible Innovation, 2019 | 6 | 2019 |
| Dangerous diagnostics? Regulatory reform in the genomic era K Holloway, FA Miller, A Gutierrez, S Hogarth Bmj 364, 2019 | 5 | 2019 |
| Teaching conflict: Professionalism and medical education KJ Holloway Journal of bioethical inquiry 12 (4), 675-685, 2015 | 5 | 2015 |
| Conflict of interest as ethical shorthand: understanding the range and nature of “non-financial conflict of interest” in biomedicine Q Grundy, C Mayes, K Holloway, S Mazzarello, BD Thombs, L Bero Journal of Clinical Epidemiology 120, 1-7, 2020 | 4 | 2020 |
| Half a century of Wilson & Jungner: reflections on the governance of population screening S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ... Wellcome Open Research 5, 2020 | 2 | 2020 |
| Blood donation and the global COVID-19 pandemic: areas for social science research J Haw, K Holloway, B Masser, EM Merz, R Thorpe SocArXiv, 2020 | 1 | 2020 |
| A Troubled Solution: Medical Student Struggles with Evidence and Industry Bias KJ Holloway Science and engineering ethics 21 (6), 1673-1689, 2015 | 1 | 2015 |
| Patient advocacy, drug promotion, and the feminist paradox: An analysis of the Canadian Pain Coalition K Holloway, J Haw Health Tomorrow: Interdisciplinarity and Internationality 1 (1), 2013 | 1 | 2013 |
| 9 Public Good, or Goods for the Public: The Commercialization of Academic Health Research K HOLLOWAY, M HERDER Health Matters: Evidence, Critical Social Science, and Health Care in Canada …, 2020 | | 2020 |
| The Consultant's intermediary role in the regulation of molecular diagnostics in the US K Holloway, FA Miller Social Science & Medicine, 112929, 2020 | | 2020 |
| Responses to “Health Canada needs to act on laboratory-developed diagnostics” K Holloway, FA Miller, F Rousseau, A Gutierrez, S Hogarth CMAJ 192 (10), E261-E261, 2020 | | 2020 |
| The Organized Response to the “War on Science” and the Lost Potential for Challenging Commercialization K Holloway TOPIA: Canadian Journal of Cultural Studies 36, 173-190, 2016 | | 2016 |
| Emerging Researchers and Intellectual Property: Law, Policy and Practice K Holloway | | 2015 |
| The Pharmaceutical Industry and Student Resistance: A Political Economy Perspective on Pharmaceutical Industry Influence in Medical Education in the United States and Canada K Holloway | | 2013 |
| Governance of Population Screening [version 1; peer review S Sturdy, F Miller, S Hogarth, N Armstrong, P Chakraborty, C Cressman, ... | | |
